KCNH2
Voltage-gated inwardly rectifying potassium channel KCNH2
As of the edition of 20 October 2026, KCNH2 (voltage-gated inwardly rectifying potassium channel KCNH2, UniProt Q12809) has 6 drugs tested at it and 12 companies on the list, 1 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q12809
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 23
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Infections; Lungs and airways; Cancer; Chemically induced; Digestive system; Pregnancy and women's health
- Registered trials of its drugs
- 104
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Amiodarone | Marketed | Phase 4 | none listed |
| Sotalol | Marketed | Phase 4 | none listed |
| AZD1305 | Went quiet | Phase 2 | none listed |
| Vernakalant | Marketed | Phase 4 | none listed |
| Ibutilide | Marketed | Phase 4 | none listed |
| Dofetilide | Marketed | Phase 2 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 3 |
| Engaged | 3 |
| Undetermined | 5 |
| Total on the list | 12 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Legacy Pharma Inc Sezc | Route B |
| Cipher Pharmaceuticals | Route B |
The other 9 companies at KCNH2
In the product12 companies in all; 9 are not named here, and no score is.
See the 12 companies at KCNH2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.